Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The company’s shares opened today at $159.99. Don't Miss our Black ...

Highlights:,Biogen Inc. (BIIB) has underperformed the broader market and key healthcare ETFs in recent years.,The company’s ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares ...

We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has ...

Advancements and Projections in the Neurology Clinical Trials Market: Insights, Trends, Opportunities, and Recent ...

Parliament's winter session began with disruptions as the opposition clashed with the ruling party. Prime Minister Modi accused the opposition of obstructing proceedings, while the INDIA bloc ...

A man walks past a corporate office of Adani Group in Gurugram, India, November 22, 2024. REUTERS/Priyanshu Singh/File Photo Adani dollar bond prices fell to almost one-year lows on Monday as ...